kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression

被引:123
作者
Chao, CC
Gekker, G
Hu, SX
Sheng, WS
Shark, KB
Bu, DF
Archer, S
Bidlack, JM
Peterson, PK
机构
[1] UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55404
[2] RENSSELAER POLYTECH INST,COGSWELL LAB,DEPT CHEM,TROY,NY 12181
[3] UNIV ROCHESTER,SCH MED,DEPT PHARMACOL,ROCHESTER,NY 14642
关键词
U50,488; U69,593;
D O I
10.1073/pnas.93.15.8051
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Microglial cells, the resident macrophages of the brain, play an important role in the neuropathogenesis of human immunodeficiency virus type 1 (HIV-1), and recent studies suggest that opioid peptides regulate the function of macrophages from somatic tissues. We report herein the presence of kappa opioid receptors (KORs) in human fetal microglia and inhibition of HIV-1 expression in acutely infected microglial cell cultures treated with KOR ligands, Using reverse transcriptase-polymerase chain reaction and sequencing analyses, we found that mRNA for the KOR was constitutively expressed in microglia and determined that the nucleotide sequence of the open reading frame was identical to that of the human brain KOR gene. The expression of KOR in microglial cells was confirmed by membrane binding of [H-3]U69,593, a kappa-selective ligand, and by indirect immunofluorescence. Treatment of microglial cell cultures with U50,488 or U69,593 resulted in a dose-dependent inhibition of expression of the monocytotropic HIV-1 SF162 strain, This antiviral effect of the kappa ligands was blocked by the specific KOR antagonist, nor-binaltrophimine. These findings suggest that kappa opioid agonists have immunomodulatory activity in the brain, and that these compounds could have potential in the treatment of HIV-1-associated encephalopathy.
引用
收藏
页码:8051 / 8056
页数:6
相关论文
共 50 条
  • [1] [Anonymous], NEUROBIOLOGY OPIATES
  • [2] THE KAPPA-OPIOID RECEPTOR IS PRIMARILY POSTSYNAPTIC - COMBINED IMMUNOHISTOCHEMICAL LOCALIZATION OF THE RECEPTOR AND ENDOGENOUS OPIOIDS
    ARVIDSSON, U
    RIEDL, M
    CHAKRABARTI, S
    VULCHANOVA, L
    LEE, JH
    NAKANO, AH
    LIN, XQ
    LOH, HH
    LAW, PY
    WESSENDORF, MW
    ELDE, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) : 5062 - 5066
  • [3] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF THE BRAIN
    ATWOOD, WJ
    BERGER, JR
    KADERMAN, R
    TORNATORE, CS
    MAJOR, EO
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (04) : 339 - 366
  • [4] KAPPA-OPIOID AGONIST MODULATION OF [H-3] THYMIDINE INCORPORATION INTO DNA - EVIDENCE FOR THE INVOLVEMENT OF PERTUSSIS TOXIN-SENSITIVE G-PROTEIN-COUPLED PHOSPHOINOSITIDE TURNOVER
    BARG, J
    BELCHEVA, MM
    ROWINSKI, J
    COSCIA, CJ
    [J]. JOURNAL OF NEUROCHEMISTRY, 1993, 60 (04) : 1505 - 1511
  • [5] EVALUATION OF DELAYED TREATMENT OF FOCAL CEREBRAL-ISCHEMIA WITH 3 SELECTIVE KAPPA-OPIOID AGONISTS IN CATS
    BASKIN, DS
    WIDMAYER, MA
    BROWNING, JL
    HEIZER, ML
    SCHMIDT, WK
    [J]. STROKE, 1994, 25 (10) : 2047 - 2053
  • [6] KAPPA-OPIOID BINDING-SITES ON A MURINE LYMPHOMA CELL-LINE
    BIDLACK, JM
    SARIPALLI, LD
    LAWRENCE, DMP
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 227 (03): : 257 - 265
  • [7] Caroleo M. Cristina, 1994, Neuroimmunomodulation, V1, P141, DOI 10.1159/000097148
  • [8] OPIOID RECEPTORS ON CELLS OF THE IMMUNE-SYSTEM - EVIDENCE FOR DELTA-CLASS AND KAPPA-CLASS
    CARR, DJJ
    DECOSTA, BR
    KIM, CH
    JACOBSON, AE
    GUARCELLO, V
    RICE, KC
    BLALOCK, JE
    [J]. JOURNAL OF ENDOCRINOLOGY, 1989, 122 (01) : 161 - 168
  • [9] EXOGENOUS AND ENDOGENOUS OPIOIDS AS BIOLOGICAL RESPONSE MODIFIERS
    CARR, DJJ
    SEROU, M
    [J]. IMMUNOPHARMACOLOGY, 1995, 31 (01): : 59 - 71
  • [10] UP-REGULATION OF HIV-1 EXPRESSION IN COCULTURES OF CHRONICALLY INFECTED PROMONOCYTES AND HUMAN BRAIN-CELLS BY DYNORPHIN
    CHAO, CC
    GEKKER, G
    HU, SX
    SHENG, WS
    PORTOGHESE, PS
    PETERSON, PK
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 50 (05) : 715 - 722